Company intelligence / Profile preview

Ainthoven

Ownership: Private
Employees: ~3
Development stage: Preclinical

Overview

Ainthoven is an early-stage company developing AI-driven platforms for biologic drug discovery and optimization. Their technology aims to address antibiotic resistance, cancer immunotherapy, and precision medicine. No clinical results are reported yet as the company is at the MVP-building stage.

Therapeutic areas: OncologyInfectious Diseases
Modalities: BiologicAI-driven drug discovery
Industry: Drug Discovery Services

Partnerships

Select biopharmaceutical and biotechnology companies for joint development of novel medicines (no specific partners named)

Beyond the preview

Go deeper on Ainthoven.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ainthoven.

Explore the full profile